Predicting serious liver scarring in hepatitis B patients

This study looks at whether simple blood tests can help predict liver scarring (fibrosis) in people with fatty liver disease. If you join, you'll have a quick, non-invasive scan of your liver to check for fat and scarring.

This study aims to develop better ways to measure how much fibrosis (scarring) in the liver improves after treatment for NASH (fatty liver with inflammation). If you have moderate to severe liver scarring from NASH, this research could help doctors track your condition more precisely, which may lead to more effective care.

This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.

This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.

This study is testing a new way to predict if people with chronic hepatitis B, who also have liver fibrosis or cirrhosis, might develop liver cancer (HCC). It uses your medical data to create a risk score, which could help you and your doctor plan earlier and more tailored monitoring.

This study is looking for new ways to detect liver scarring (fibrosis) in people with fatty liver disease (NAFLD, NASH, MASLD, or MASH). If you qualify, you will give a blood sample to help identify biomarkers that could replace biopsies.